|Mr. Jeffrey D. Abbey||Pres, CEO & Director||832.98k||N/A||1962|
|Dr. Charles A. Nicolette Ph.D.||Chief Scientific Officer and VP of R&D||465.54k||N/A||1962|
|Dr. Richard D. Katz||VP & CFO||N/A||N/A||1964|
|Ms. Lori R. Harrelson CPA||VP of Fin. & Principal Accounting Officer||N/A||N/A||1969|
|Mr. John D. Menditto||VP of Corp. Communications and Investor Relations||N/A||N/A||N/A|
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.
Argos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.